Goldman Sachs Upgrades Protagonist Therapeutics (PTGX) to Buy

August 10, 2026 4:12 AM

Goldman Sachs analyst Richard Law upgraded Protagonist Therapeutics (NASDAQ: PTGX) from Neutral to Buy with a price target of $186.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found